Escaping big pharma’s pricing with patent-free drugs
The New York Times - 07/18/2017
But clearly there’s room for more nonprofit drug companies. “D.N.D.I.’s success is ample proof that the model of nonprofit, open-source research and development is a viable alternative to exclusive reliance on patent and data monopolies,” said Brook Baker, a professor at Northeastern University School of Law who studies pharmaceutical development issues. Recent reports on the crisis of access to medicines by the United Nations and the British medical journal The Lancet single out D.N.D.I. as evidence that different approaches to research and development can provide improved efficiency and affordability.